Marius Pharmaceuticals, a pharmaceutical company dedicated to developing innovative therapies for testosterone deficiency, has partnered with Duke University School of Medicine to explore the ...

The TRAVERSE trial, a large-scale clinical study with over 5,000 patients, published in 2023, concluded that TRT does not increase the risk of adverse cardiovascular outcomes in men with hypogonadism.

Evansville, Indiana - Domestic Supply has introduced Testosterone Undecanoate, a product intended to support muscle retention and performance in athletes. This product is designed ...

RALEIGH, N.C., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals is pleased to announce that Thrive, a leading provider of personalized healthcare solutions and a trusted partner of O2 Fitness, ...

Testosterone undecanoate is under clinical development by Marius Pharmaceuticals and currently in Phase I for Male Infertility. According to GlobalData, Phase I drugs for Male Infertility does not ...